Form 4: Sage Therapeutics Director Michael Cola Granted Stock Option Award

Director Michael Cola of Sage Therapeutics, Inc. received a stock option award on June 10, 2024, under the company's 2024 Equity Incentive Plan.

Summary

• Michael Cola, a director at Sage Therapeutics, Inc., was granted a stock option on June 10, 2024.
• The option allows him to purchase 12,500 shares of common stock at an exercise price of $10.90 per share.
• The stock option was issued under the Sage Therapeutics, Inc. 2024 Equity Incentive Plan, as part of the Non-Employee Director Compensation Program.
• The option will vest in full on the earlier of June 10, 2025, or the day before the 2025 Annual Meeting of Sage's stockholders, contingent upon continued service as a director.
• Brandon Marsh, acting as Attorney-in-Fact for Michael F. Cola, signed the report on June 11, 2024.

Sentiment

Score: 7

Explanation: The document reflects a standard director compensation practice, indicating a stable and ongoing business operation. The sentiment is neutral to slightly positive.

Positives

• The stock option grant aligns the director's interests with those of the shareholders.
• The vesting schedule incentivizes continued service as a director.

Future Outlook

The director's stock option will vest based on continued service, aligning his interests with the company's long-term performance.

Industry Context

Stock option grants are a common form of compensation for directors, aligning their interests with shareholders and incentivizing long-term value creation.

Comparison to Industry Standards

• Director compensation packages, including stock options, vary widely across the biotechnology industry depending on company size, stage of development, and performance.
• Comparing Sage Therapeutics' director compensation to peers like Biogen, Vertex Pharmaceuticals, or smaller biotech firms would provide a better understanding of its relative competitiveness.
• Typical vesting schedules for director stock options range from one to three years, with some companies offering immediate vesting upon grant.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of the shareholders, potentially leading to better corporate governance and decision-making.
• The grant has a minimal direct impact on employees, customers, suppliers, and creditors.

Key Dates